Quetiapine Fumarate Tablet, Extended Release
Product Images NDC 16729-132

5 FDA label images from Accord Healthcare Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Quetiapine Fumarate (NDC 16729-132). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Accord Healthcare Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Quetiapine Fumarate Extended-release Tablets Bottle Label 30 Tablets (Quetiapine 50mg 30 Tablets)

Quetiapine Fumarate Extended-release Tablets Bottle Label 30 Tablets (Quetiapine 50mg 30 Tablets)
The label for Quetiapine Extended-Release Tablets USP 50 mg from Accord Healthcare Inc. shows it is an oral extended-release tablet, packaged with 30 tablets. The label includes the NDC 16729-132-10, usage instruction as 'Once Daily,' and a warning to swallow whole without crushing or chewing. Manufacturer details list Accord Healthcare Inc. and Intas Pharmaceuticals Limited, India.*
FDA Label Image

Figure 1 Kaplan-meier Curves Of Time To Schizophrenic Relapse Study 3.jpg (Quetiapine Figure 1)

Figure 1 Kaplan-meier Curves Of Time To Schizophrenic Relapse Study 3.jpg (Quetiapine Figure 1)
A line graph depicting the proportion of patients with relapse (%) on the y-axis over time in months on the x-axis. Two lines compare relapse rates: one labeled PLA with a stepped dashed line and another labeled QTP XR with a stepped solid line. The graph shows changes in relapse proportions over a 7-month period.*
FDA Label Image

Figure 2 Kaplan-maier Curves Of Time To Recurrence Of A Mood Event.jpg (Quetiapine Figure 2)

Figure 2 Kaplan-maier Curves Of Time To Recurrence Of A Mood Event.jpg (Quetiapine Figure 2)
A Kaplan-Meier survival curve showing the proportion of patients with relapse over time in weeks. Two groups are compared: one receiving Quetiapine Fumarate plus lithium/valproate (QTP+LI/VAL) indicated by a dashed line, and the other receiving placebo plus lithium/valproate (PLA+LI/VAL) indicated by a solid line. The graph shows relapse percentages on the y-axis ranging from 0 to 100%.*
FDA Label Image

Figure 3 Kaplan-meier Curves Of Time To Recurrence Of A Mood Event (study 19).jpg (Quetiapine Figure 3)

Figure 3 Kaplan-meier Curves Of Time To Recurrence Of A Mood Event (study 19).jpg (Quetiapine Figure 3)
A line graph depicting the proportion of patients with relapse (%) over time (weeks), comparing two groups labeled QTP+ LIVAL and PLA+ LIVAL. The x-axis represents time in weeks up to 100 weeks, and the y-axis represents the relapse proportion from 0% to 100%. The graph shows the rate of relapse increasing over time for both groups, with the PLA+ LIVAL group having a higher relapse proportion throughout the time period.*
FDA Label Image

Structural Formula (Quetiapine Structure)

Structural Formula (Quetiapine Structure)
Chemical structure of quetiapine fumarate, showing the quetiapine moiety and the fumarate counterion.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.